NCT00485030已完成4 期
Comparison Between Drug-Eluting Stents for the Treatment of the Diffuse Type In-Stent Restenosis After Drug-Eluting Stents Implantation: Sirolimus-Eluting vs. Paclitaxel-Eluting Stents
Seung-Jung Park16 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2007年3月1日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 16
- 主要终点
- Binary in-segment angiographic restenosis
研究概览
简要总结
To evaluate the best therapeutic option for the treatment of diffuse type post-drug-eluting stent restenosis.
详细描述
Despite a significant reduction of angiographic restenosis and the need for repeat revascularization after introduction of DES, post-DES restenosis still occur and the treatment for DES failure is challenging. However, there have been little data for therapeutic strategy for post-DES restenosis, especially diffuse type ISR. Therefore, we need the well-designed randomized trial to achieve the best therapeutic option for the treatment of diffuse type post-DES restenosis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient must be at least 18 years of age.
- •Restenosis after drug-eluting stents (>50% by visual estimate)
- •Lesion length ≥ 10 mm (diffuse type ISR)
- •Patients with stable (CCS class 1 to 4) or acute coronary syndromes (unstable angina pectoris Braunwald class IB, IC, IIB, IIC, IIIB, IIIC or NSTEMI) or patients with atypical chest pain or without symptoms but having documented myocardial ischemia, amenable to stent-assisted percutaneous coronary intervention
- •The patient or guardian agrees to the study protocol and the schedule of clinical and angiographic follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.
排除标准
- •The patient has a known hypersensitivity or contraindication to any of the following medications:
- •Both Clopidogrel and TIclopidine
- •Sirolimus eluting stent
- •Stainless steel and/or
- •Contrast media (patients with documented sensitivity to contrast which can be effectively pre-medicated with steroids and diphenhydramine [e.g. rash] may be enrolled. Patients with true anaphylaxis to prior contrast media, however, should not be enrolled).
- •Systemic (intravenous) Sirolimus use within 12 months.
- •Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study.
- •History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia), or will refuse blood transfusions.
- •Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery within 2 months.
- •Current known current platelet count <100,000 cells/mm3 or Hgb <10 g/dL.
- •Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment).
- •Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.
- •Patients with EF<30%.
- •Acute MI patients within symptom onset < 12 hours needing primary angioplasty
- •Creatinine level 3.0mg/dL or dependence on dialysis.
- •Severe hepatic dysfunction (AST and ALT 3 times upper normal reference values).
- •Patients with left main stem stenosis and left main in-stent restenosis created by DES(>50% by visual estimate)
结局指标
主要结局
Binary in-segment angiographic restenosis
时间窗: at 9 months angiographic follow-up
次要结局
- The composite of death, myocardial infarction, and target-vessel revascularization(in-hospital, 1 month, and 9 months after index procedure)
- stent thrombosis(in-hospital, 1 month, and 9 months after index procedure)
- Late luminal loss(at 8 month angiographic follow-up)
- Procedural success defined as achievement of a final diameter stenosis of <30% by QCA using any percutaneous method, without the occurrence of death, Q wave MI, or repeat revascularization of the target lesion(during the hospital stay)
研究者
Seung-Jung Park
MD,PhD, Chairman,Heart Institute, Asan Medical Center,University of Ulsan,College of Medicine
CardioVascular Research Foundation, Korea
研究点 (16)
Loading locations...
相似试验
终止
4 期
Drug-Eluting Stent Implantation Versus Optimal Medical Treatment in Patients With Chronic Total Occlusion (DECISION-CTO)Coronary Artery DiseaseNCT01078051Seung-Jung Park840
已完成
不适用
Optimal Treatment for Coronary Drug Eluting Stent In-stent RestenosisCoronary Stent RestenosisNCT04862052Semmelweis University Heart and Vascular Center108
撤回
不适用
Clinical Of Drug-eluting Stent Versus Excimer Laser Ablation Combined Drug-coated Balloon To Treat Arteriosclerosis Occlusive Disease Of Lower ExtremityIschemiaAtherosclerosisNCT05575245Xuanwu Hospital, Beijing
已完成
不适用
Drug Eluting Stent Zilver PTX vs Bare Metal Stent Zilver FlexVascular DiseasesNCT05296031Skane University Hospital49
招募中
不适用
Prospective Evaluation of Drug-Eluting Stents in Routine Clinical Practice (ASAN PCI Registry)Coronary Artery DiseaseNCT01788592Seung-Jung Park50,000